Clinically Relevant Insights
Tests analyze risk variants identified from genome-wide studies of >100K patients with breast or prostate cancer.
A comprehensive genomic map of cancer risk.
Map the landscape of prostate and breast cancer risk using whole-genome sequencing to calculate personalized, clinically integrated risk scores to support proactive care plans.
>1M
genetic risk factors analyzed
5-yr or 10-yr
risk reported
5–6 weeks
turnaround time from samples received
Blood or buccal
sample types accepted
What Atlas measures
Integrated Risk tests combine polygenic risk scores (PRS) from whole-genome sequencing with clinical inputs from a patient's health history to reveal cancer risks that traditional assessments and single-gene risk screening may miss. As science advances and clinical profiles evolve, the same whole-genome dataset can be reanalyzed for new insights — no new sample required.
Actionable Reports
Results include clear metrics and next steps aligned with breast or prostate cancer guidelines.
Validated Cross-Ancestry Performance
Proprietary ancestry decomposition technology enables accurate risk prediction across diverse populations, validated in >130K patients with breast or prostate cancer.
Why this matters
Risk beyond single-gene testing
~95%
of individuals do not have a single-gene cancer condition
But may still carry polygenic cancer risk.¹
20%
of breast cancers have a genetic cause undetected by single-gene analysis
Single-gene tests miss these genetic risk factors.²
~60%
of breast and prostate cancer risk is heritable
Detectable as genetic markers by the iPRS test.³,⁴
1. Garber JE, Offit K. J Clin Oncol. 2005;23:276–292. 2. Wendt C, Margolin S. Acta Oncologica. 2019;58(2):135–146. 3. Sokolova A, et al. Histopathology. 4. Zero Prostate Cancer. ZERO. 2025.
Test Offerings
Proactive screening
Integrated Risk
Polygenic risk scores combined with clinical factors deliver highly accurate, personalized risk scores for serious cancers — capturing a layer of risk that single-gene testing alone can miss.
Breast cancer
Combines whole-genome insights, personal and family history, and clinical factors to provide a 5-year and lifetime risk estimate for developing breast cancer.
Learn More
Prostate cancer
Combines whole-genome insights, personal and family history, and clinical factors to provide a 10-year and/or lifetime risk estimate for developing prostate cancer.
Learn MoreOrdering & logistics
Two Ordering Options, One Atlas Experience
Atlas Cancer Plus
Leverages whole-genome sequencing for comprehensive insights across coding and non-coding regions, with re-analysis on the same sample as new scores launch.
Test codes
BreastPR41003
ProstatePR41034
Atlas Cancer Select
Uses high-coverage exome plus low-coverage whole-genome sequencing — a cost-effective option for preventative health decisions, with re-analysis on the same sample as new scores launch.
Test codes
BreastPR42009
ProstatePR42038
Turnaround times
From samples received, most results are delivered in 5 to 6 weeks. Follow-up testing or re-requisitions for existing MyOme patients are typically completed in under 2 weeks, often within a few days.
Sample Types Accepted
- Blood
- Buccal (cheek swab)
Important considerations
What a risk score can and cannot tell you
Integrated Risk tests are intended as proactive risk screening tools — they are not diagnostic tests.
Integrated Risk tests detect millions of polygenic risk factors — they do not detect high impact variants associated with monogenic cancers (e.g., BRCA1 and BRCA2).
Some individuals with high scores won't develop cancer, and some with low scores will.
Map your risk, guide lifelong health.
We're here at every step — from ordering and sample collection to interpreting results with your patients.